- English
-
Legal Services
Fiduciary Services
- AIFM & UCITS Management Company Services
- Accounting, Tax & Agency Services
- Commodity Pool Operator Services
- Company Secretarial & Board Support Services
- Conflict Review & Advisory Services
- Directorship Services
- Facilities Agent Services
- Permanent Office Solutions
- Power of Attorney & Proxy Agent Services
- Private Client Services
- Trustee Services
Fund Services
Regulatory & Compliance
-
Americas and Caribbean
Europe
-
PUT YOUR CAREER INTO GEAR
-
Maples Group's Global Asset Finance Team Recognised Again on Aviation Finance Deals of the Year
02 May 2024Maples Group Receives Continued Recognition for Information Security Management with ISO 27001 Certification
01 May 2024 -
EMIR Refit Key Changes and Considerations
01 May 2024
Deals
Maples Advises on First Royalty-Backed Financing in China's Biopharmaceutical Industry
04 May 2022
Maples and Calder, the Maples Group's law firm, is pleased to have acted as Cayman Islands counsel to R-Bridge Healthcare Fund, a private fund of healthcare-focused firm CBC Group ("CBC") on a US$40 million royalty-backed financing for Yisheng Biopharma Co., Ltd., a China-based biopharmaceutical company. The proceeds will be allocated to develop the vaccines targeting COVID-19, cancer and infectious diseases.
A team based in the Group's law firm in Singapore acted as Cayman Islands counsel to CBC on this market-first transaction. The team was led by Asia Finance Partner, James Kinsley with assistance from Associate, Rebecca Lee.
CBC is Asia’s largest healthcare-dedicated investment firm with US$5 billion assets under management. As a leading investor-operator, CBC partners with healthcare entrepreneurs and scientists to deliver innovative solutions and improve healthcare efficiency and quality for all. R-Bridge Healthcare Fund operates within the CBC platform and provides healthcare companies with bespoke, non-dilutive financing backed by Asia-sourced healthcare royalty, revenue interests and through a range of alternative financing structures, the first of its kind in the asset class in China.
Commenting on this transaction, James Kinsley said, "China's biopharmaceutical industry has seen dramatic development in recent years and has been actively innovating in technologies, business models, and enterprise management. We are very pleased to have had the privilege of advising CBC on this ground breaking transaction as this represents the first royalty-backed financing in this industry."
CBC was advised by Sidley Austin LLP and Yisheng Biopharma was advised by Clifford Chance.
Related Services
Finance
Fund Finance
Related Contacts
Related Articles
-
Announcements
Maples Group's Global Asset Finance Team Recognised Again on Aviation Finance Deals of the Year
02 May 2024
-
Announcements
Maples Group Hires Yann Hilpert, Growing its Luxembourg Asset Finance, Fund Finance, Securitisation and Capital Markets Capabilities
02 May 2024
-
Announcements
58 Maples Group Lawyers and 16 Practice Groups Recognised in The Legal 500 EMEA 2024 Guide
29 Apr 2024
-
Maples Group Advances AI Strategy with Global Rollout of Harvey AI Partnership
11 Mar 2024
-
Deals
Maples Group Advises on Landmark Financing Arrangement to Luxembourg Securitisation Undertaking
20 Feb 2024
-
Announcements
Maples Group Announces 2024 Global Partner and Of Counsel Promotions
20 Feb 2024
-
Announcements
Maples Group "Top Class" and "Go to Firm" According to 2024 Chambers Global Guide
15 Feb 2024
-